Epidemiological and clinical studies have provided growing evidence for links between chronic stress, depression, social isolation and cancer progression. In the present work, our data provide a new understanding of the mechanisms by which chronic stress contributes to tumor progression. Specifically, our findings indicate that tumoral dopamine levels are depleted under chronic stress. Dopamine replacement blocked the growth stimulatory effects of chronic stress. On the basis of these findings, dopamine analogues may represent a novel therapeutic strategy.
Introduction
The stress response is a complex process arising from interactions between environmental contexts and the organism's evaluation of potential threat and its capacity to respond. These factors initiate a cascade of information processing in both central and peripheral nervous systems as well as hormonal cascades. (1) This results in activation of the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis (2, 3) . Norepinephrine and epinephrine are known to be elevated in the plasma and tumor microenvironment of individuals with acute and chronic stress (4, 5) . We have recently demonstrated that both norepinephrine and epinephrine levels are elevated in a sustained fashion in ovarian and other peritoneal tissues in preclinical models of chronic stress (6) . These hormonal increases were related to greater tumor burden, which was mediated by increased angiogenesis. Recent evidence suggests that the third catecholamine, dopamine, has the opposite effect with regard to effects on tumor angiogenesis, growth and development of ascites (7, 8) . In vivo and in vitro studies have shown that dopamine, via its specific DR2 receptors, inhibits tumor growth by suppressing the actions of vascular permeability factor/vascular endothelial growth factor-A (VPF/VEGF) on both tumor endothelial cells and bone-marrow-derived endothelial progenitor cells (9) . Dopamine inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 phosphorylation (10) (11) (12) , and inhibits MAP kinase and focal adhesion kinase activation (12) . Dopamine can also inhibit mobilization of endothelial progenitor cells (EPCs) from the bone marrow (13) .
It is known that dopamine levels are increased in the brain during acute stress (14) . In contrast, under chronic stress conditions, dopamine levels are lower as a consequence of decreased release of dopamine (15) . However, it is not known whether dopamine levels are depleted in the tumor microenvironment in response to chronic stress. Moreover, it is not known whether dopamine can counteract the stimulatory effects of norepinephrine on tumor growth. These 
Materials and Methods
Reagents. Dopamine (DA), bromocriptine (dopamine receptor 2 (DR2)-agonist), eticlopride (DR2-antagonist), SKF 3839 (DR1 agonist), butaclamol (DR1 antagonist) and norepinephrine (NE) were obtained from Sigma Aldrich (Detroit, MI); recombinant human VEGF from R&D Systems (Minneapolis, MN). Annexin V-and Tunel staining kits were purchased from BD Pharmingen (San Diego, CA) and Promega (Madison, WI) respectively.
Cell lines and culture conditions. The ovarian non-transformed (HIO-180) and cancer cells (SKOV3ip1, HeyA8, A2780. RMG2 and IGROV) were maintained in RPMI1640, 15% FBS and 0.1% gentamicin sulfate (Gemini Bioproducts, Calabasas, CA) (16, 17) . Endothelial cells isolated from the mesentery or ovary of the immortomouse (MOEC) were a kind gift from Dr.
Robert Langley (18) and were maintained in DMEM,10% FBS. All in vitro experiments were conducted at 60% to 80% confluence, unless otherwise specified. For in vivo injections, cancer cells were trypsinized and centrifuged at 1000 rpm for 7 min at 4°C, washed twice, and reconstituted in Hank's balanced salt solution (Gibco, Carlsbad, CA).
Determination of dopamine concentration in tumor and normal tissue. Dopamine levels were determined by HPLC-EC in the College of Pharmacy at the University of Iowa. The method uses electrochemical detection to quantitate dopamine levels; HPLC is used to separate one catecholamine from another. Values were calculated by comparing the peak height of the unknown (sample) to that of a pure standard of known concentration, these were expressed in pg dopamine/mg wet tissue.
RT-PCR analysis of dopamine receptors.
Total RNA was isolated by using Qiagen RNeasy kit. cDNA was synthesized by using the SuperScript First-Strand kit (Invitrogen) as per the manufacturer's instructions. cDNA was subjected to PCR using specific primers sequences for human dopamine receptors (DR1-DR5) previously reported (19) . Specific primers sequences for murine dopamine receptors (DR1-DR5) were designed based on the reported NCBI-nucleotide sequences using the Oligo Perfect software (Invitrogen). ȕ-actin was used as a housekeeping gene.
Short interfering RNA (siRNA) preparation. Specific siRNA sequences targeted against murine dopamine receptor 2 (DR2) (duplex of: 5'GAUUCACUGUGACAUCUUU and 5AAAGAUGUCACAGUGAAUC) and human DR2 (duplex of: 5'CACACAUCCUGAACAUCA and 5'UGUAUGUUCAGGAUGUGUG) were obtained from Sigma Aldrich. These sequences were incorporated into chitosan nanoparticles (CH) using a gelation method of anionic tripolyphosphate (TPP) (20) . Briefly, predetermined TPP (0.25% w/v) and siRNA (1 μg/μL) were added in CH solution, resulting in siRNA-CH-NP generated under constant stirring at room temperature. After incubating at 4°C for 40 min, the siRNA-CH was collected by centrifugation (Thermo Biofuge, Germany) at 12,000 rpm for 40 min at 4°C. The CH-NPs were purified 3 times and stored at 4°C until used.
Chronic stress model and treatment schema. Female athymic nude and immunocompetent (C57BL6) mice (10 to 12-week-old) were obtained from the US National Cancer Institute. All experiments were approved by the Institutional Animal Care and Use Committee of the M.D.
Anderson Cancer Center. The animals were experimentally stressed using a well-characterized restraint system, in which periodic immobilization induces high levels of HPA and SNS activity characteristic of chronic stress (6) . Ovarian cancer cells were injected intraperitoneally into mice 7 days after starting daily stress applied for 2 hours. Then, mice were further divided into treatment groups (10 animals/group) as follows: 1) control PBS, 2) dopamine (75 mg/kg daily Cell viability assay. To examine the effect of dopamine on cell viability, MTT assay was performed as previously described (21) .
Cyclic AMP determination. The effect of dopamine on cAMP accumulation was examined exposing cells to 0, 10 and 50 ȝM dopamine for 30 min at 37°C. cAMP levels were measured in total cell lysates using an enzyme immunoassay-kit (Biomol, PA).
Cell Invasion assay. Invasion through human-defined matrix was assessed using the Membrane Invasion Culture System (MICS), as previously described (22 reprobing membranes with an anti-ȕ actin antibody (Sigma Aldrich). To examine the association between GĮi1 protein and DR2, MOEC cells were exposed to 10 ȝM dopamine for 0, 10 and 30 min at 37° C. Cell lysates were than prepared and immunoprecipitated with DR2 antibody at 4°C for 2 hours. Immunocomplexes were captured with 2% protein A-agarose beads (Upstate).
Protein was eluted in reducing sample Laemmli buffer, subjected to 10% SDS-PAGE separation and transferred to a nitrocellulose membrane. Anti-GĮi (Abcam) was used as primary antibody.
Immunodetection of GĮi1 protein was performed as described above.
Immunohistochemistry. Analysis of microvessel density (MVD) and assessment of tumor and endothelial cell apoptosis was performed following procedures previously described (18, 21, 23, 24) . Double Immunofluorescence for DR2/CD31 and for DR2/Tunel was performed in frozen tissue-sections as follows: after acetone-fixation and blocking with gelatin (4%), tissues were incubated with rabbit DR2 antibody (Santa Cruz-Biotech, (1:100) at 4 ºC overnight. Samples were washed in PBS and incubated with blocking solution for 10 minutes and then with a goat anti-rabbit Alexa 488 antibody (1:1000) for 1 hour. Afterwards, tissues were subjected to CD31
and Tunel stainings, as previously described. (18, 21, 23, 24) .
Immunofluorescence and confocal microscopy.
Immunofluorescence microscopy was performed using a Zeiss Axioplan fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY) equipped with a 100-W Hg lamp and narrow bandpass excitation filters. Representative images were obtained using a cooled chargecoupled device Hamamatsu C5810 camera (Hamamatsu Photonics,Bridgewater, NJ) and 
Results
Dopamine levels during chronic stress. We determined dopamine and norepinephrine concentrations in tumors and peritoneal tissues including ovary, liver, and omentum from mice subjected to daily stress for 1, 3 , 7 or 14 days. NE levels increased after 1 day of stress and remained elevated until day 14 in all tissues samples. In contrast, DA concentrations increased significantly after 1 day of stress, but declined after 3 to 14 days of stress in tumor, ovarian and omental tissues (Supplementary Figure 1) .
Dopamine-dose-response in vivo.
We have previously demonstrated that chronic stress establishes favorable conditions for promoting angiogenesis in the tumor microenvironment by SNS activation (6) . Since the levels of the anti-angiogenic catecholamine, dopamine, are decreased in the tumor microenvironment under chronic stress, we asked whether dopamine could block the stimulatory effects of SNS on ovarian cancer growth. Prior to performing such blocking experiments, we first tested several doses of dopamine to identify the lowest dose required for inhibiting cancer growth in non-stressed or stressed mice. SKOV3ip1-tumor bearing nude mice (n=10 per group) were treated with either: 1) control PBS, 2) dopamine 50 mg/kg, 3) dopamine 75 mg/kg, or 4) dopamine 100 mg/kg. Treatment was started 1 week after injection of SKOV3ip1-ovarian cancer cells. In stressed mice, doses of 75 and 100 mg/kg significantly reduced tumor growth (p<0.05), with the greatest decrease noted at the 75 mg/kg dose. All three doses significantly decreased the number of tumor nodules (p<0.05) compared to controls (Supplementary Figure 2A) . In contrast, in non-stressed mice no significant changes in tumor weight or tumor nodules were observed at any of the dopamine doses tested. Given the known effects of dopamine on angiogenesis (7), we also assessed MVD. There was a significant reduction in MVD at all dopamine doses tested (p<0.05; Supplementary Figure 2B ). Dopamine 75 mg/kg was selected for all subsequent in vivo experiments due to its inhibitory effect on cancer growth. 
reversed the protective effects of dopamine ( Figure 1B ). These data suggest that dopamine indeed acted through DR2 to block stress mediated ovarian cancer growth. Dopamine targets murine endothelial and human cancer cells. To further examine whether the inhibitory effects of dopamine were mediated by targeting (host) endothelial and/or (human) tumor cells through their corresponding DR2 receptors, we utilized siRNA incorporated into chitosan nanoparticles. The specificity of siRNA sequences for mouse and human DR2, was confirmed using RT-PCR (Supplementary Figure 4) . SKOV3ip1-tumor bearing mice were divided into 4 experimental groups: 1) control siRNA, 2) dopamine alone, 3) dopamine + mDR2-siRNA and 4) dopamine + hDR2-siRNA; each group was used for both non-stress and stress conditions ( Figure 1C ). In daily stressed mice, dopamine treatment significantly blocked tumor weight (67%) and the number of tumor nodules (65%). This growth inhibitory effect of dopamine was significantly abrogated by dopamine/mDR2-siRNA-CH, but not by dopamine/hDR2-siRNA-CH combined treatment (p=0.02; Figure 1C ). These results suggest that in the SKOV3ip1 model, dopamine mediated effects occur primarily through DR2 on endothelial cells. The effects of dopamine were also tested in a second ovarian cancer model, HeyA8 ( Figure 1D ). Compared to mice injected with control siRNA, dopamine treatment blocked tumor growth by 84% (p=0.007) and resulted in a 63% decrease in the number of nodules (p=0.02). Interestingly, in this model both, both dopamine/mDR2-siRNA-CH and dopamine/hDR2-siRNA-CH treatments significantly blocked the inhibitory effects of dopamine Effect of dopamine on angiogenesis and cell viability. Given the known effects of catecholamines on angiogenesis, we examined microvessel density in the SKOV3ip1-tumors harvested from dopamine treated animals. In stressed mice, dopamine-treatment resulted in a significant reduction (61%) in MVD compared to controls (Figure 2A ; p<0.01). In contrast, dopamine/eticlopride treatment led to a significant increase (Figure 2A compared to dopamine-treated mice. We also examined effects on tumor cell apoptosis since it is known that norepinephrine can reduce sensitivity of cancer cells to apoptosis (19) . Tissues from dopamine-treated mice revealed a 2.2-fold increase (p<0.01) in tumor cell apoptosis compared to control tissues (Figure 2A) . The combined dopamine/eticlopride treatment abrogated the dopamine-mediated effects on cell apoptosis. In addition, the combined treatment of dopamine/mDR2siRNA and dopamine/hDR2-siRNA-CH reversed the effects of dopamine on MVD (p<0.01) and cell apoptosis (p<0.01; Figure 2B explored whether it could affect other steps in the metastatic cascade. We examined the effects of dopamine on cell invasion. We analyzed the effect of dopamine and various dopamine agonists and antagonists on the invasive potential of SKVO3ip1 cells. Dopamine 10 ȝM, inhibited VPF/VEGF induced cell invasion (22) by 59% (p<0.05; Fig. 4) , as did the DR2 agonist bromocriptine (56%; p<0.05). However, the DR1 agonist SKF 38393 (50 ȝM) had no effect.
Eticlopride (50 ȝM), a specific DR2 receptor antagonist, significantly abrogated the dopaminemediated inhibition of cancer cell invasion (p<0.01). These results further suggest that the inhibitory action of dopamine on cell invasion was mediated specifically through DR2.
We also examined whether dopamine can block the stimulatory effect of norepinephrine on SKOV3ip1-cell invasion, previously described by our group (25) . Dopamine blocked the NEmediated effect by 61% (p<0.05) in SKOV3ip1 cells exposed to NE plus dopamine. In addition, the combined treatment of dopamine/NE/VEGF led to a 52% reduction (p<0.001) in cell invasion compared to NE/VEGF-treatment, indicating the ability of DA to counteract the stimulatory effects of NE and VEGF on cell invasion (Figure 4 ).
Dopamine decreases cAMP levels in MOEC and SKOV3ip1 cells. Dopamine, acting through
G-protein coupled receptors, exerts stimulatory (DR1, DR5) or inhibitory (DR2-DR4) effects on adenylate cyclase leading to increased and decreased intracellular cAMP levels, respectively.
We examined the effects of dopamine on cAMP levels in MOEC and SKOV3ip1 cells. Our in vitro data confirmed that dopamine decreases intracellular cAMP levels in MOEC as well as in SKOV3ip1 cells. This strongly suggested that dopamine could be acting through the DR2-cAMP-signaling pathway to exert its inhibitory effects in vivo on tumor growth. To address this question, we examined the association of DR2 to GĮi1 protein in MOEC exposed to dopamine (10 ȝM) for 10 and 30 min. There was a 1.6-fold increase in the interaction between DR2 and GĮi1 protein after 10 min of dopamine-exposure, compared to untreated cells ( Figure 5C ).
Research. 
Discussion
The main findings of this study are that dopamine significantly reduces stress-mediated cancer growth in ovarian carcinoma. Our data strongly suggest that dopamine retards tumor growth by inhibiting tumor angiogenesis and stimulating tumor cell apoptosis. In addition, we provide the first evidence that dopamine is able to block the stimulatory effects of chronic stress on cancer growth.
The physiological actions of dopamine are mediated by at least 5 distinct G-protein-coupled receptor subtypes. (26, 27) . Two DR1-like receptor subtypes (DR1 and DR5) couple to the G protein Gs, activate adenylate cyclase and increase cAMP levels. The other receptor subtypes belong to the DR2-like subfamily (DR2, DR3 and DR4) and are prototypic of G protein-coupled receptors that inhibit adenylate cyclase and decrease cAMP production. The ovarian nontransformed, cancer and endothelial cells tested in this work showed expression of DR1 and DR2-like dopamine receptors, indicating that dopamine might regulate stimulatory and/or inhibitory processes in these cells. Dysfunction of dopaminergic system is known to be associated with various disorders, including schizophrenia and Parkinson's disease (28) . The consequences of dopamine dysfunction indicate the importance of maintaining dopamine functionality through homeostatic mechanisms based on the delicate balance between synthesis, storage, release, metabolism and reuptake (28) . A decrease in dopamine in the brain has been implicated as the cause of Parkinson's disease. In contrast, it is argued that a functional excess of DA or oversensitivity of certain DR's is one of the causal factors in schizophrenia (29) . Interestingly, the incidence of cancer in patients with schizophrenia has been reported to be lower than in the general population (30) (31) (32) . Whether this reduced incidence is related to hyperactive dopaminergic system is not known. It has been demonstrated that dopamine concentrations are lower in the tumor microenvironment compared to normal tissues (11, 33) . These findings prompted us to consider whether the increases in tumor growth and angiogenesis may result from a permissive microenvironment created by a relative shift toward growth-promoting catecholamines. In the present study, we demonstrate that dopamine blocks stress induced tumor growth by activating DR2. The central role of DR2 was confirmed with the DR2-antagonist eticlopride in combination therapy with dopamine, as well as with siRNA targeted against murine or human DR2. The dopamine-suppressing effect on tumor growth in our stress models was significantly blunted by DR2 gene silencing. These findings indicate that dopamine targets both host murine endothelial cells and human cancer cells through DR2 to exert its growth suppressive effects. Our results are supported by the reported growth inhibitory effects of dopamine under non-stress conditions (7, 9, 34) .
Our data also indicate that dopamine, via DR2, blocked the VPF/VEGF or norepinephrine mediated invasion of ovarian cancer cells. The inhibitory effects of dopamine on cell invasion would explain, in part, the in vivo blocking effect of dopamine on tumor progression and metastasis under chronic stress. Our in vitro studies demonstrate that dopamine decreases viability not only of endothelial cells, as previously described, (7, 12) oral) have also been used clinically to treat hyperprolactinemia and are well tolerated (39) .
Furthermore, effective shrinkage of prolactinomas has been observed after injection of longacting form of Parlodel (40) . Such agents may represent a new strategy for blocking the effects of chronic stress on tumor growth. With such therapies, however, some adverse reactions such as nausea, hallucinations, and orthostatic hypotension have been reported and would require careful monitoring.
To identify the signaling pathways by which dopamine affects endothelial and ovarian cancer cell function, we examined the effects of dopamine on phophorylation and activation of various effectors in the metastatic cascade. In MOEC, dopamine inhibited VEGF-induced phophorylation and activaton of Src kinase. In addition, dopamine reversed NE-stimulated Srcphosphorylation. Src is a key mediator for multiple signaling pathways that regulate critical cellular functions (41) . In ovarian cancer, Src has been shown to play a functional role in cancer cell invasion and angiogenesis (42) . Src is also a regulator of VEGF-mediated vascular permeability (43) . Recent studies in HUVEC have shown that dopamine reduces VEGFmediated permeability by inhibiting VEGF-induced Src activation (44) . These studies coupled with our data implicate blockade of Src activation as a key mediator of the inhibitory effects of dopamine on ovarian cancer growth.
Overall, our data suggest that dopamine inhibits stress hormone stimulated Src activation in endothelial and ovarian cancer cells. Moreover, we conclude that dopamine-replacement effectively counteracts the stimulatory effects of norepinephrine on ovarian cancer growth during chronic stress. Considering the stimulatory effects of chronic stress on cancer growth (6), our findings implicate dopamine as a potential therapeutic strategy for blocking the deleterious effects of chronic stress. 
